Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
- Author:
Sang Ouk CHIN
1
;
Cheol Ryong KU
;
Byung Joon KIM
;
Sung Woon KIM
;
Kyeong Hye PARK
;
Kee Ho SONG
;
Seungjoon OH
;
Hyun Koo YOON
;
Eun Jig LEE
;
Jung Min LEE
;
Jung Soo LIM
;
Jung Hee KIM
;
Kwang Joon KIM
;
Heung Yong JIN
;
Dae Jung KIM
;
Kyung Ae LEE
;
Seong Su MOON
;
Dong Jun LIM
;
Dong Yeob SHIN
;
Se Hwa KIM
;
Min Jeong KWON
;
Ha Young KIM
;
Jin Hwa KIM
;
Dong Sun KIM
;
Chong Hwa KIM
Author Information
- Publication Type:Review
- Keywords: Acromegaly; Somatostatin; Octreotide; Lanreotide; Pasireotide
- MeSH: Acromegaly; Expert Testimony; Growth Hormone; Humans; Octreotide; Pituitary Neoplasms; Somatostatin
- From:Korean Journal of Medicine 2019;94(6):485-494
- CountryRepublic of Korea
- Language:Korean
- Abstract: Acromegaly is a chronic disorder caused by excessive growth hormone (GH) secretion. In most cases, the excess GH originates from GH-producing pituitary adenomas. Surgery is the preferred first-line treatment for patients with acromegaly, but medical management is considered when the disease persists after surgery or in cases where patients refuse surgery or are poor candidates for surgery. Somatostatin analogues are commonly used to treat acromegaly. The Korean Endocrine Society and the Korean Neuroendocrine Study Group have developed a position statement for the use of somatostatin analogues in the medical treatment of acromegaly. This position statement is based on evidence from the current literature and expert opinions. In the case of discrepancies among expert opinions, the experts voted to determine the recommended approach.
